FDA Roundup: December 27, 2024
FDA Roundup: December 27, 2024
FDA Roundup: December 27, 2024
Small robots directed by magnetic fields can cooperatively lift heavy objects, form floating rafts and push through clogs. They may one day deliver drugs within…
The US Defense Advanced Research Projects Agency demonstrated the first at-sea refueling of the No Manning Required Ship program.
Explore this post and more from the Futurology community
Emerging infectious diseases pose a persistent global health threat, with the potential to cause widespread morbidity, mortality, and significant social and economic disruptions. Postdoctoral researcher…
A third-year medical student’s research on the detection of cholangiocarcinoma earned top prize at 2023 AMA Research Challenge. Learn more.
These unsettling systems like something out of a sci-fi nightmare are becoming more pervasive as militaries look to them for modern warfare.
Efficacy and safety of brilaroxazine for schizophrenia sustained for > 1 year in open-label extension of RECOVER, announced by Reviva Pharmaceuticals.
New tumour types are being described at increasing frequency, and most new tumour types are now identified via retrospective review of next-generation sequencing data. This…
Foundation models will be brand DNA, hands-free will be redefined and we’ll hit the AI trust tipping point (among other developments).
Warren Buffett has bought stakes in three companies, after hoarding cash for most of 2024.